Literature DB >> 23055189

ING4 is negatively correlated with microvessel density in colon cancer.

Chun Lou1, Shixiong Jiang, Xinggang Guo, Xin-shu Dong.   

Abstract

ING4 is a novel tumor suppressor which is downregulated in a number of cancers. In this study, we investigated the role of ING4 in tumor angiogenesis in colorectal carcinoma (CRC) patients. Semi-quantitative RT-PCR, western blots, and immunohistochemistry were used to determine ING4 mRNA and protein expression in CRC and normal tissue from 60 CRC specimens and 30 colonic adenoma specimens. The correlation between ING4 expression and clinical stage, histological grade as well as lymph node metastasis was evaluated. Immunohistochemistry was performed to explore the correlation between ING4 expression and microvessel density (MVD) in CRC. CRC tissue had significantly lower levels of ING4 mRNA and protein compared to colonic adenoma and normal intestinal tissue. Immunostaining showed ING4 expression in 38 (63.3 %), 30 (100 %), and 60 (100 %) cases of normal colonic mucosa, adenoma, and normal intestinal mucosal tissue, respectively. Lower ING4 levels correlated with higher clinical stage and histological grade. ING4 mRNA and protein levels were significantly lower in CRC patients with lymph node metastasis compared to patients without lymph node metastasis (0.41 ± 0.30 vs. 0.91 ± 0.29 and 0.60 ± 0.21 vs. 0.87 ± 0.27, respectively; p < 0.001). Importantly, ING4 mRNA and protein levels were negatively correlated with MVD in CRC patients (p < 0.001). Our data suggest that ING4 levels are a potential biomarker of CRC progression and that ING4 may inhibit tumor growth by modulating angiogenesis in CRC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23055189     DOI: 10.1007/s13277-012-0498-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  41 in total

1.  Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.

Authors:  Jennifer M Rubatt; Kathleen M Darcy; Alan Hutson; Sarah M Bean; Laura J Havrilesky; Lisa A Grace; Andrew Berchuck; Angeles Alvarez Secord
Journal:  Gynecol Oncol       Date:  2009-01-09       Impact factor: 5.482

2.  Synergistic tumor suppression by adenovirus-mediated inhibitor of growth 4 and interleukin-24 gene cotransfer in hepatocarcinoma cells.

Authors:  Yufeng Xie; Haitao Lv; Weihua Sheng; Jingcheng Miao; Jim Xiang; Jicheng Yang
Journal:  Cancer Biother Radiopharm       Date:  2011-10-11       Impact factor: 3.099

Review 3.  Regulation of HIF by prolyl hydroxylases: recruitment of the candidate tumor suppressor protein ING4.

Authors:  Abdullah Ozer; Richard K Bruick
Journal:  Cell Cycle       Date:  2005-09-19       Impact factor: 4.534

Review 4.  The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis.

Authors:  Daniel J Brat; Anita C Bellail; Erwin G Van Meir
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

5.  Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer.

Authors:  Arup Bhattacharya; Steve G Turowski; Ivan Dominguez San Martin; Ashwani Rajput; Youcef M Rustum; Robert M Hoffman; Mukund Seshadri
Journal:  Anticancer Res       Date:  2011-02       Impact factor: 2.480

Review 6.  Colorectal cancer prevention.

Authors:  Ernest T Hawk; Bernard Levin
Journal:  J Clin Oncol       Date:  2005-01-10       Impact factor: 44.544

Review 7.  Colorectal cancer.

Authors:  David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

8.  Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma.

Authors:  Feng Fang; Lai-Bang Luo; Yi-Ming Tao; Fan Wu; Lian-Yue Yang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02       Impact factor: 4.254

9.  Sialyl Lewis X expression and lymphatic microvessel density in primary tumors of node-negative colorectal cancer patients predict disease recurrence.

Authors:  Fania S Doekhie; Hans Morreau; Geertruida H de Bock; Frank M Speetjens; N Geeske Dekker-Ensink; Hein Putter; Cornelis J H van de Velde; Rob A E M Tollenaar; Peter J K Kuppen
Journal:  Cancer Microenviron       Date:  2008-08-06

10.  Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis.

Authors:  S Rasheed; A L Harris; P P Tekkis; H Turley; A Silver; P J McDonald; I C Talbot; R Glynne-Jones; J M A Northover; T Guenther
Journal:  Br J Cancer       Date:  2009-05-19       Impact factor: 7.640

View more
  13 in total

1.  ING4 enhances paclitaxel's effect on colorectal cancer growth in vitro and in vivo.

Authors:  Liyu Cao; Shunhua Chen; Cong Zhang; Cong Chen; Nana Lu; Yan Jiang; Yongping Cai; Yu Yin; Jianming Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Identification of the inhibitor of growth protein 4 (ING4) as a potential target in prostate cancer therapy.

Authors:  Aymen Shatnawi; Sridhar A Malkaram; Tamer Fandy; Efrosini Tsouko
Journal:  Mol Cell Biochem       Date:  2019-11-27       Impact factor: 3.396

3.  Tumor suppressor ING4 overexpression contributes to proliferation and invasion inhibition in gastric carcinoma by suppressing the NF-κB signaling pathway.

Authors:  Shijie Li; Tianli Fan; Hongtao Liu; Jiangtao Chen; Changjiang Qin; Xuequn Ren
Journal:  Mol Biol Rep       Date:  2013-09-22       Impact factor: 2.316

4.  Recombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition.

Authors:  Chuan-Jiang Wang; Dong Yang; Ying-Wei Luo
Journal:  Exp Ther Med       Date:  2015-05-22       Impact factor: 2.447

5.  Expression of ING4 is negatively correlated with cellular proliferation and microvessel density in human glioma.

Authors:  Bin Shao; Enzhong Liu
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

Review 6.  INGs are potential drug targets for cancer.

Authors:  Runyun Zhang; Jianhua Jin; Juanjuan Shi; Yongzhong Hou
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-20       Impact factor: 4.553

Review 7.  Inhibitor of growth-4 is a potential target for cancer therapy.

Authors:  Shuping Yuan; Jianhua Jin; Juanjuan Shi; Yongzhong Hou
Journal:  Tumour Biol       Date:  2016-01-23

8.  Reduced expression and prognostic implication of inhibitor of growth 4 in human osteosarcoma.

Authors:  Dahang Zhao; Xiangjie Liu; Yunge Zhang; Zhaoming Ding; Feng Dong; Hongwei Xu; Baoxin Wang; Wenbo Wang
Journal:  Oncol Lett       Date:  2016-03-09       Impact factor: 2.967

9.  ING4 regulates JWA in angiogenesis and their prognostic value in melanoma patients.

Authors:  J Lu; Y Tang; Y Cheng; G Zhang; A Yip; M Martinka; Z Dong; J Zhou; G Li
Journal:  Br J Cancer       Date:  2013-10-24       Impact factor: 7.640

10.  Delivery of inhibitor of growth 4 (ING4) gene significantly inhibits proliferation and invasion and promotes apoptosis of human osteosarcoma cells.

Authors:  Mei Li; Ye Zhu; Hongbin Zhang; Lihua Li; Peng He; Hong Xia; Yu Zhang; Chuanbin Mao
Journal:  Sci Rep       Date:  2014-12-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.